11:00-12:00

Registration

12:00-13:00

Molecular Tumor Board Sírio-Libanês

13:00-13:40

Lunch

13:40-13:45

Welcome e Introductions  

Dr. Jorge Sabbaga and Dr. Denis Jardim

13:45-14:00

Molecular techniques to detect somatic and germline alterations (NGS, WES)

Dr. Michael Berger

14:00–14:05

Discussion

14:05-14:20

Interpretation and functional impact of Variants of Unknown Significance on genetic tests

Dra. Dirce Carraro

14:20-14:25

Discussion

14:25–14:40

Pathology assessment of tumors and implications upon somatic and germline alterations

Dra. Mariana Petaccia

14:40 -14:45

Discussion

14:45–15:00

Applicability and interpretation of current genetic tests available for germline alterations

Dr. Benedito Rossi

15:00 -15:05

Discussion

15:05–15:25

Interval

15:25–15:40

Genetic counseling pre and post molecular tests

Dra. Maria Isabel Achatz

15:40-15:45

Discussion

15:45-16:00

Clinical interpretation of molecular tests for the detection of somatic genetic alterations in tissue and circulating tumor DNA

Dr. Michael Berger

16:00-16:05

Discussion

16:05-16:20

Molecular tests and immunotherapies – mutational load, immune signatures, microsatellite instability

Dr. Fernando Santini

16:20-16:25

Discussion

16:25-16:40

Molecular tests for the diagnosis of Unknown Primary neoplasia

Dr. Gilberto Castro

16:40-16:45

Discussion

16:45-17:00

What is the evidence and levels of recommendation for targeted therapies directed for genomic alterations

Dr. Denis Jardim

17:00-17:05

Discussion

17:05-17:20

Experiences, challenges and accomplishments during the implementation of a Institutional Molecular Tumor Board

Dr. Michael Berger

17:20-17:25

Discussion

17:20-17:40

How precision oncology will evolve for the next years – all

17:40-18:10

Final remarks and visit to HSL Facilities